Conditions: Clinical Stage II Esophageal Adenocarcinoma AJCC v8; Clinical Stage III Esophageal Adenocarcinoma AJCC v8; Clinical Stage III Gastric Cancer AJCC v8; Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IV Esophageal Adenocarcinoma AJCC v8; Clinical Stage IV Gastric Cancer AJCC v8; Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Locally Advanced Esophageal Adenocarcinoma; Locally Advanced Gastric Adenocarcinoma; Locally Advanced Gastroesophageal Junction Adenocarcinoma; Metastatic Esophageal Adenocarcinoma; Metastatic Gastric Adenocarcinoma; Metastatic Gastroesophageal Junction Adenocarcinoma; Unresectable Esophageal Adenocarcinoma; Unresectable Gastric Adenocarcinoma; Unresectable Gastroesophageal Junction Carcinoma
Interventions: Procedure: Biospecimen Collection; Procedure: Computed Tomography; Drug: Futibatinib; Procedure: Magnetic Resonance Imaging; Drug: Paclitaxel; Biological: Ramucirumab
Sponsors: Northwestern University; National Cancer Institute (NCI)
Not yet **RECRUITING NOW**
Interventions: Procedure: Biospecimen Collection; Procedure: Computed Tomography; Drug: Futibatinib; Procedure: Magnetic Resonance Imaging; Drug: Paclitaxel; Biological: Ramucirumab
Sponsors: Northwestern University; National Cancer Institute (NCI)
Not yet **RECRUITING NOW**
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
